The effect of bisphosphonates on bone metastasis of hormone-refractory prostate cancer

Acta Urologica Japonica

Volumn 52, Issue 6, 2006, Pages 491-494

  Tanaka, Tomoaki ^a   Kawashima, Hidenori ^a   Kuratsukuri, Katsuyuki ^a   Sugimura, Kazunobu ^a   Nakatani, Tatsuya ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Bisphosphonate; Bone metabolic markers; Bone metastasis; Hormone refractory; Prostate cancer

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; NARCOTIC AGENT; PLACEBO; ZOLEDRONIC ACID;

BONE ATROPHY; BONE METASTASIS; BONE PAIN; CELL SURVIVAL; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG EFFICACY; HORMONE RESISTANCE; HUMAN; HYPERCALCEMIA; OSTEOCLAST; PALLIATIVE THERAPY; PATHOLOGIC FRACTURE; PROSTATE CANCER; QUALITY OF LIFE; REVIEW; SPINAL CORD COMPRESSION;

ANTINEOPLASTIC AGENTS; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; DIPHOSPHONATES; HUMANS; IMIDAZOLES; MALE; PROSTATIC NEOPLASMS;

EID: 33745739987     PISSN: 00181994     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. Adami S: Bisphosphonates in prostate carcinoma. Cancer 80: 1674-1679, 1997
2. Coleman RE: Bisphosphonates: clinical experience. Oncologist 9: 14-27, 2004
3. Body JJ, Bartl R, Burckhardt P, et al.: Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. J Clin Oncol 16: 3890-3899, 1998
4. Fleisch H: Bisphosphonates: mechanisms of action. Endocr Rev 19: 80-100, 1998
5. Carey PO and Lippert MC: Treatment of painful prostatic bone metastases with oral etidronate disodium. Urology 32: 403-407, 1988
6. Smith JA Jr: Palliation of painful bone metastases from prostate cancer using sodium etidronate: results of a randomized, prospective, double-blind, placebo-controlled study. J Urol 141: 85-87, 1989
7. Heidenreich A, Hofmann R and Engelmann UH: The use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer. J Urol 165: 136-140, 2001
8. Heidenreich A, Elert A and Hofmann R: Ibandronate in the treatment of prostate cancer associated painful osseous metastases. Prostate Cancer P D 5: 231-235, 2002
9. Saad F, Gleason DM, Murray R, et al.: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94: 1458-1468, 2002
10. Saad F, Gleason DM, Murray R, et al.: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96: 879-882, 2004
11. Saad F, Karakiewicz P and Perrotte P: The role of bisphosphonates in hormone-refractory prostate cancer. World J Urol 23: 14-18, 2005
12. Fleisch H: Bisphosphonates: mechanisms of action and clinical use in osteoporosis-an update. Horm Metab Res 29: 145-150, 1997
13. Rogers MJ, Frith JC, Luckman SP, et al.: Molecular mechanisms of action of bisphosphonates. Bone 24: 73S-79S, 1999
14. Benford HL, Frith JC, Auriola S, et al.: Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. Mol Pharmacol 56: 131-140, 1999
15. Oades GM, Senaratne SG, Clarke IA, et al.: Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells. J Urol 170: 246-252, 2003
16. Coxon JP, Oades GM, Kirby RS, et al.: Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation. BJU Int 94: 164-170, 2004
17. Stokkel M, Zwinderman A, Zwartendijk J, et al.: The value of pretreatment clinical and biochemical parameters in patients with newly diagnosed untreated prostate carcinoma and no indications for bone metastases on the bone scintigram. Eur J Nucl Med 24: 1215-1220, 1997
18. Cher ML, Bianco FJ Jr, Lam JS, et al.: Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J Urol 160: 1387-1391, 1998
19. Maeda H, Koizumi M, Yoshimura K, et al.: Correlation between bone metabolic markers and bone scan in prostatic cancer. J Urol 157: 539-543, 1997
20. Tamada T, Sone T, Tomomitsu T, et al.: Biochemical markers for the detection of bone metastasis in patients with prostate cancer: diagnostic efficacy and the effect of hormonal therapy. J Bone Miner Metab 19: 45-51, 2001
21. Koizumi M, Yonese J, Fukui I, et al.: Metabolic gaps in bone formation may be a novel marker to monitor the osseous metastasis of prostate cancer. J Urol 167: 1863-1866, 2002
22. Koizumi M, Takahashi S and Ogata E: Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis. Anticancer Res 23: 4095-4099, 2003
23. Tannock IF, de Wit R, Berry WR, et al.: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502-1512, 2004
24. Petrylak DP, Tangen CM, Hussain MH, et al.: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351: 1513-1520, 2004
25. Ullen A, Lennartsson L, Harmenberg U, et al.: Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid. Acta Oncol 44: 644-650, 2005